Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI toolkit aims to speed up epidemic response for diseases like COVID-19 and mpox

NCT ID NCT07678619

Knowledge-focused Sponsor: Peking University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Aug 20, 2026 · Updated 3 times

Summary

This study tests a new AI-powered toolkit designed to help public health officials at local CDC offices respond more quickly to emerging infectious diseases such as COVID-19, mpox, influenza, and dengue. The toolkit combines data analysis, risk assessment, decision support, and evaluation tools. Around 780 CDC staff across five Chinese provinces will use the toolkit alongside their usual methods, and their response times will be compared to those who follow routine practices only.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SMART-ID Toolkit (AI-driven decision-support software)
What this could lead to
If successful, this AI toolkit could help public health officials respond to outbreaks faster and more effectively, potentially saving lives during future epidemics.
What could go wrong
This is a relatively small, early-stage study in five Chinese provinces. The toolkit may not work as well in other regions or with different diseases, and real-world effectiveness remains unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 108 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Working at a participating district/county-level CDC in one of the five provinces/municipalities (Zhejiang, Guangdong, Hubei, Sichuan, or Shanghai) where at least one emerging infectious disease (COVID-19, mpox, influenza, dengue, chikungunya, or avian influenza) has occurred. * Being one of the three designated participants from the participating CDC cluster: one CDC director or relevant leader responsible for infectious disease prevention and control, or one of two professional staff members engaged in acute infectious disease surveillance, risk assessment, decision-making, risk management, or emergency response. * Currently responsible for or involved in infectious disease epidemic prevention and control work, including information collection, risk perception, risk assessment, decision-making, risk management, and emergency response at the CDC. * Willing to voluntarily participate in this study and provide written informed consent. Exclusion Criteria: * Under 18 years of age. * Diagnosed with severe mental illness or other conditions that impede normal communication. * Employed in the current CDC position for less than 1 year.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Avian influenza are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

avian influenza chikungunya Communicable Diseases, Emerging COVID-19 dengue disease infectious disease influenza monkeypox

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Avian influenza Chikungunya fever COVID -19 Dengue fever Emerging infectious diseases Influenza Mpox (monkeypox)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Jue Liu

    Beijing, Beijing Municipality, 100191, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.